Exact Mass: 361.1314

Exact Mass Matches: 361.1314

Found 95 metabolites which its exact mass value is equals to given mass value 361.1314, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Pyriminobac-methyl

methyl 2-(4,6-dimethoxypyrimidin-2-yl)oxy-6-(N-methoxy-C-methylcarbonimidoyl)benzoate

C17H19N3O6 (361.1274)


Pyriminobac-methyl is a herbicide used on rice. Herbicide used on rice

   

bisacodyl

bisacodyl

C22H19NO4 (361.1314)


A - Alimentary tract and metabolism > A06 - Drugs for constipation > A06A - Drugs for constipation > A06AB - Contact laxatives A - Alimentary tract and metabolism > A06 - Drugs for constipation > A06A - Drugs for constipation > A06AG - Enemas C78276 - Agent Affecting Digestive System or Metabolism > C29697 - Laxative D005765 - Gastrointestinal Agents > D002400 - Cathartics D005765 - Gastrointestinal Agents > D054368 - Laxatives Bisacodyl is a stimulant laxative agent that works directly on the colon to produce a bowel movement. Bisacodyl increases the secretion of PGE2 by direct activation of colon macrophages. PGE2 acts as a paracrine factor and decreases the expression of AQP3 in the colon, which inhibits water transfer from the luminal to the vascular side and leads to a laxative effect[1].

   

De-O-methylsimmondsin

2-[(1E)-2,4-dihydroxy-3-methoxy-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}cyclohexylidene]acetonitrile

C15H23NO9 (361.1373)


De-O-methylsimmondsin is found in coffee and coffee products. De-O-methylsimmondsin is a constituent of jojoba meal. Constituent of jojoba meal. Demethylsimmondsin is found in coffee and coffee products, fats and oils, and nuts.

   

Benoxathian

[(2,3-dihydro-1,4-benzoxathiin-2-yl)methyl][2-(2,6-dimethoxyphenoxy)ethyl]amine

C19H23NO4S (361.1348)


D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents

   

Bisacodyl

4-{[4-(acetyloxy)phenyl](pyridin-2-yl)methyl}phenyl acetic acid

C22H19NO4 (361.1314)


A - Alimentary tract and metabolism > A06 - Drugs for constipation > A06A - Drugs for constipation > A06AB - Contact laxatives A - Alimentary tract and metabolism > A06 - Drugs for constipation > A06A - Drugs for constipation > A06AG - Enemas C78276 - Agent Affecting Digestive System or Metabolism > C29697 - Laxative D005765 - Gastrointestinal Agents > D002400 - Cathartics D005765 - Gastrointestinal Agents > D054368 - Laxatives Bisacodyl is a stimulant laxative agent that works directly on the colon to produce a bowel movement. Bisacodyl increases the secretion of PGE2 by direct activation of colon macrophages. PGE2 acts as a paracrine factor and decreases the expression of AQP3 in the colon, which inhibits water transfer from the luminal to the vascular side and leads to a laxative effect[1].

   

Nitroflurbiprofen

4-(Nitrooxy)butyl 2-fluoro-alpha-methyl-(1,1-biphenyl)-4-acetic acid

C19H20FNO5 (361.1325)


C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic C471 - Enzyme Inhibitor > C1323 - Cyclooxygenase Inhibitor

   

Ptemc

3-(2-(Phenylthio)ethyl)-5-methoxycarbonyl-4-methyl-2,6-dimethyl-1,4-dihydropyridine-3-carboxylate

C19H23NO4S (361.1348)


   

Pyriminobac-methyl, (Z)-

Methyl 2-[(4,6-dimethoxypyrimidin-2-yl)oxy]-6-[1-(methoxyimino)ethyl]benzoic acid

C17H19N3O6 (361.1274)


   
   

Leptoclinidamine B

Leptoclinidamine B

C16H19N5O5 (361.1386)


   

SAR102608

SAR102608

C20H16FN5O (361.1339)


CONFIDENCE standard compound; INTERNAL_ID 1359; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4212; ORIGINAL_PRECURSOR_SCAN_NO 4209 CONFIDENCE standard compound; INTERNAL_ID 1359; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4285; ORIGINAL_PRECURSOR_SCAN_NO 4280 CONFIDENCE standard compound; INTERNAL_ID 1359; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4295; ORIGINAL_PRECURSOR_SCAN_NO 4294 CONFIDENCE standard compound; INTERNAL_ID 1359; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4294; ORIGINAL_PRECURSOR_SCAN_NO 4293 CONFIDENCE standard compound; INTERNAL_ID 1359; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4304; ORIGINAL_PRECURSOR_SCAN_NO 4303 CONFIDENCE standard compound; INTERNAL_ID 1359; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4291; ORIGINAL_PRECURSOR_SCAN_NO 4288 CONFIDENCE standard compound; INTERNAL_ID 1359; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8805; ORIGINAL_PRECURSOR_SCAN_NO 8804 CONFIDENCE standard compound; INTERNAL_ID 1359; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8813; ORIGINAL_PRECURSOR_SCAN_NO 8811 CONFIDENCE standard compound; INTERNAL_ID 1359; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8820; ORIGINAL_PRECURSOR_SCAN_NO 8818 CONFIDENCE standard compound; INTERNAL_ID 1359; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8838; ORIGINAL_PRECURSOR_SCAN_NO 8833 CONFIDENCE standard compound; INTERNAL_ID 1359; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8848; ORIGINAL_PRECURSOR_SCAN_NO 8844 CONFIDENCE standard compound; INTERNAL_ID 1359; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8849; ORIGINAL_PRECURSOR_SCAN_NO 8848

   
   

2-Butyl-5-hydroxy-7-(4-hydroxyphenyl)-6H-benzo[de]isoquinoline-1,6(2H)-dione

2-Butyl-5-hydroxy-7-(4-hydroxyphenyl)-6H-benzo[de]isoquinoline-1,6(2H)-dione

C22H19NO4 (361.1314)


   

Me glycoside,N,2,4,6-tetra-Ac-alpha-D-Pyranose-3-Amino-3-deoxyglucose|Me glycoside,N,2,4,6-tetra-Ac-beta-D-Pyranose-3-Amino-3-deoxyglucose

Me glycoside,N,2,4,6-tetra-Ac-alpha-D-Pyranose-3-Amino-3-deoxyglucose|Me glycoside,N,2,4,6-tetra-Ac-beta-D-Pyranose-3-Amino-3-deoxyglucose

C15H23NO9 (361.1373)


   
   
   
   

N4-Anisoyl-2-deoxycytidine

N4-Anisoyl-2-deoxycytidine

C17H19N3O6 (361.1274)


relative retention time with respect to 9-anthracene Carboxylic Acid is 0.797 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.800 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.794

   

Varenicline Tartrate

Varenicline Tartrate

C17H19N3O6 (361.1274)


D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018679 - Cholinergic Agonists D000077444 - Smoking Cessation Agents Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation[1][2][3][4][5]. Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation[1][2][3][4][5].

   

1,N2-4-Oxo-2-hexenal-deoxyguanosine

1,N2-4-Oxo-2-hexenal-deoxyguanosine

C16H19N5O5 (361.1386)


   

Asp Gly Gly Asn

(2S)-2-(2-{2-[(2S)-2-amino-3-carboxypropanamido]acetamido}acetamido)-3-carbamoylpropanoic acid

C12H19N5O8 (361.1234)


   

Asp Gly Asn Gly

(3S)-3-amino-3-[({[(1S)-2-carbamoyl-1-[(carboxymethyl)carbamoyl]ethyl]carbamoyl}methyl)carbamoyl]propanoic acid

C12H19N5O8 (361.1234)


   

Asp Asn Gly Gly

(3S)-3-amino-3-{[(1S)-2-carbamoyl-1-({[(carboxymethyl)carbamoyl]methyl}carbamoyl)ethyl]carbamoyl}propanoic acid

C12H19N5O8 (361.1234)


   

Gly Asp Gly Asn

(2S)-2-{2-[(2S)-2-(2-aminoacetamido)-3-carboxypropanamido]acetamido}-3-carbamoylpropanoic acid

C12H19N5O8 (361.1234)


   

Gly Asp Asn Gly

(3S)-3-(2-aminoacetamido)-3-{[(1S)-2-carbamoyl-1-[(carboxymethyl)carbamoyl]ethyl]carbamoyl}propanoic acid

C12H19N5O8 (361.1234)


   

Gly Gly Asp Asn

(2S)-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]-3-carboxypropanamido]-3-carbamoylpropanoic acid

C12H19N5O8 (361.1234)


   

Gly Gly Asn Asp

(2S)-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]-3-carbamoylpropanamido]butanedioic acid

C12H19N5O8 (361.1234)


   

Gly Asn Asp Gly

(3S)-3-[(2S)-2-(2-aminoacetamido)-3-carbamoylpropanamido]-3-[(carboxymethyl)carbamoyl]propanoic acid

C12H19N5O8 (361.1234)


   

Gly Asn Gly Asp

(2S)-2-{2-[(2S)-2-(2-aminoacetamido)-3-carbamoylpropanamido]acetamido}butanedioic acid

C12H19N5O8 (361.1234)


   
   
   
   
   

Asn Asp Gly Gly

(3S)-3-[(2S)-2-amino-3-carbamoylpropanamido]-3-({[(carboxymethyl)carbamoyl]methyl}carbamoyl)propanoic acid

C12H19N5O8 (361.1234)


   

Asn Gly Asp Gly

(3S)-3-{2-[(2S)-2-amino-3-carbamoylpropanamido]acetamido}-3-[(carboxymethyl)carbamoyl]propanoic acid

C12H19N5O8 (361.1234)


   

Asn Gly Gly Asp

(2S)-2-(2-{2-[(2S)-2-amino-3-carbamoylpropanamido]acetamido}acetamido)butanedioic acid

C12H19N5O8 (361.1234)


   
   
   
   
   
   

De-O-methylsimmondsin

2-[(1E)-2,4-dihydroxy-3-methoxy-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}cyclohexylidene]acetonitrile

C15H23NO9 (361.1373)


   

3-[[2-(4-benzylphenoxy)acetyl]amino]benzoic acid

3-[[2-(4-benzylphenoxy)acetyl]amino]benzoic acid

C22H19NO4 (361.1314)


   

dibenzyl 5-aminobenzene-1,3-dicarboxylate

dibenzyl 5-aminobenzene-1,3-dicarboxylate

C22H19NO4 (361.1314)


   

(2E)-2-[3-chloro-6-(4-methylpiperazin-1-yl)dibenzo[1,2-[7]annulen-11-ylidene]acetonitrile

(2E)-2-[3-chloro-6-(4-methylpiperazin-1-yl)dibenzo[1,2-[7]annulen-11-ylidene]acetonitrile

C22H20ClN3 (361.1346)


   

TRANS-3 4-BENZYLOXY-TRANS-B-NITROSTYREN&

TRANS-3 4-BENZYLOXY-TRANS-B-NITROSTYREN&

C22H19NO4 (361.1314)


   

benzyl 3-(3-aminoazetidin-1-yl)piperidine-1-carboxylate,dihydrochloride

benzyl 3-(3-aminoazetidin-1-yl)piperidine-1-carboxylate,dihydrochloride

C16H25Cl2N3O2 (361.1324)


   

3-(3-AMINOMETHYL-AZETIDIN-1-YL)-PYRROLIDINE-1-CARBOXYLIC ACID BENZYL ESTER-2HCl

3-(3-AMINOMETHYL-AZETIDIN-1-YL)-PYRROLIDINE-1-CARBOXYLIC ACID BENZYL ESTER-2HCl

C16H25Cl2N3O2 (361.1324)


   

(1-CBZ-PIPERIDIN-4-YL-AZETIDIN-3-YL)-AMINE-2HCl

(1-CBZ-PIPERIDIN-4-YL-AZETIDIN-3-YL)-AMINE-2HCl

C16H25Cl2N3O2 (361.1324)


   

N4-Bz-2-OMe-rC

N4-Bz-2-OMe-rC

C17H19N3O6 (361.1274)


N4-Benzoyl-2’-O-methylcytidine is a cytidine analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities[1].

   

(S)-4-(1-HYDROXY-2-(ISOPROPYLAMINO)ETHYL)BENZENE-1,2-DIOL (2R,3R)-2,3-DIHYDROXYSUCCINATE

(S)-4-(1-HYDROXY-2-(ISOPROPYLAMINO)ETHYL)BENZENE-1,2-DIOL (2R,3R)-2,3-DIHYDROXYSUCCINATE

C15H23NO9 (361.1373)


   

4,4-diphenylbutan-2-yl-ethyl-dimethylazanium,bromide

4,4-diphenylbutan-2-yl-ethyl-dimethylazanium,bromide

C20H28BrN (361.1405)


   

(-)-Isoproterenol tartrate

(-)-Isoproterenol tartrate

C15H23NO9 (361.1373)


   

2-(4-FORMYL-2-METHOXYPHENOXY)ACETIC ACID, N-(2-BIPHENYLYL)AMIDE

2-(4-FORMYL-2-METHOXYPHENOXY)ACETIC ACID, N-(2-BIPHENYLYL)AMIDE

C22H19NO4 (361.1314)


   

1-(3-Fluorophenyl)-6-methyl-3-(2-quinolinylmethoxy)-4(1H)-pyridazinone

1-(3-Fluorophenyl)-6-methyl-3-(2-quinolinylmethoxy)-4(1H)-pyridazinone

C21H16FN3O2 (361.1226)


   

(±)-(isopropyl)(beta,3,4-trihydroxyphenethyl)ammonium [R-(R*,R*)]-hydrogen tartrate

(±)-(isopropyl)(beta,3,4-trihydroxyphenethyl)ammonium [R-(R*,R*)]-hydrogen tartrate

C11H17NO3.C4H6O6 (361.1373)


   

Methyl 2-(2-(benzyloxycarbonylamino)propan-2-yl)-5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxylate

Methyl 2-(2-(benzyloxycarbonylamino)propan-2-yl)-5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxylate

C17H19N3O6 (361.1274)


   

Methyl 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-[(1E)-N-methoxyetha nimidoyl]benzoate

Methyl 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-[(1E)-N-methoxyetha nimidoyl]benzoate

C17H19N3O6 (361.1274)


   

TRANS-3 5-BENZYLOXY-TRANS-B-NITROSTYREN&

TRANS-3 5-BENZYLOXY-TRANS-B-NITROSTYREN&

C22H19NO4 (361.1314)


   

1-(4-Fluorophenyl)-6-methyl-3-(2-quinolinylmethoxy)-4(1H)-pyridazinone

1-(4-Fluorophenyl)-6-methyl-3-(2-quinolinylmethoxy)-4(1H)-pyridazinone

C21H16FN3O2 (361.1226)


   

N-[(4-chlorophenyl)-(2-methyl-1H-indol-3-yl)methyl]-4-methyl-2-pyridinamine

N-[(4-chlorophenyl)-(2-methyl-1H-indol-3-yl)methyl]-4-methyl-2-pyridinamine

C22H20ClN3 (361.1346)


   

5-PyriMidinecarboxaMide, N-(5-fluoro-3-Methyl-1H-indol-1-yl)-4-Methyl-2-(2-pyridinyl)-

5-PyriMidinecarboxaMide, N-(5-fluoro-3-Methyl-1H-indol-1-yl)-4-Methyl-2-(2-pyridinyl)-

C20H16FN5O (361.1339)


   

(6Z)-6-{[(1Z)-1-{[(1R)-1-Carboxy-2-methyl-2-propen-1-yl]imino}-1-hydroxy-3-sulfanyl-2-propanyl]imino}-6-hydroxynorleucine

(6Z)-6-{[(1Z)-1-{[(1R)-1-Carboxy-2-methyl-2-propen-1-yl]imino}-1-hydroxy-3-sulfanyl-2-propanyl]imino}-6-hydroxynorleucine

C14H23N3O6S (361.1307)


   

N-p-Anisoyldeoxycytidine

N-p-Anisoyldeoxycytidine

C17H19N3O6 (361.1274)


   

N-[2-(2-ethyl-5-tetrazolyl)phenyl]-3-(1-tetrazolyl)benzamide

N-[2-(2-ethyl-5-tetrazolyl)phenyl]-3-(1-tetrazolyl)benzamide

C17H15N9O (361.14)


   

6-(3-methoxyphenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine

6-(3-methoxyphenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine

C21H19N3OS (361.1249)


   

N-[2-(2-ethyl-5-tetrazolyl)phenyl]-4-(1-tetrazolyl)benzamide

N-[2-(2-ethyl-5-tetrazolyl)phenyl]-4-(1-tetrazolyl)benzamide

C17H15N9O (361.14)


   

2-Cyano-3-(4,5-dimethoxy-2-nitro-phenyl)-N-(tetrahydro-furan-2-ylmethyl)-acrylamide

2-Cyano-3-(4,5-dimethoxy-2-nitro-phenyl)-N-(tetrahydro-furan-2-ylmethyl)-acrylamide

C17H19N3O6 (361.1274)


   

(5E)-5-(1-ethylquinolin-2-ylidene)-3-methyl-1-phenyl-2-sulfanylideneimidazolidin-4-one

(5E)-5-(1-ethylquinolin-2-ylidene)-3-methyl-1-phenyl-2-sulfanylideneimidazolidin-4-one

C21H19N3OS (361.1249)


   

3-Methylbutyl (1S,5R,7R)-4-oxo-3-(thiophen-2-ylmethyl)-10-oxa-3-azatricyclo[5.2.1.01,5]dec-8-ene-6-carboxylate

3-Methylbutyl (1S,5R,7R)-4-oxo-3-(thiophen-2-ylmethyl)-10-oxa-3-azatricyclo[5.2.1.01,5]dec-8-ene-6-carboxylate

C19H23NO4S (361.1348)


   
   

N-[3-(2-chloro-10-phenothiazinyl)propyl]butane-1,4-diamine

N-[3-(2-chloro-10-phenothiazinyl)propyl]butane-1,4-diamine

C19H24ClN3S (361.1379)


   

Ethyl 4-(4-hydroxyphenyl)-2-methyl-5-oxo-3,4-dihydroindeno[1,2-b]pyridine-3-carboxylate

Ethyl 4-(4-hydroxyphenyl)-2-methyl-5-oxo-3,4-dihydroindeno[1,2-b]pyridine-3-carboxylate

C22H19NO4 (361.1314)


   
   
   
   
   
   
   
   
   

(5E)-2-(3,4-dimethylphenyl)imino-5-[(1-methylindol-3-yl)methylidene]-1,3-thiazolidin-4-one

(5E)-2-(3,4-dimethylphenyl)imino-5-[(1-methylindol-3-yl)methylidene]-1,3-thiazolidin-4-one

C21H19N3OS (361.1249)


   

PYRIMINOBAC-METHYL

(e)-pyriminobac-methyl

C17H19N3O6 (361.1274)


   

Nitroflurbiprofen

Nitroflurbiprofen

C19H20FNO5 (361.1325)


C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic C471 - Enzyme Inhibitor > C1323 - Cyclooxygenase Inhibitor

   
   

HIF-1α-IN-2

HIF-1α-IN-2

C21H19N3OS (361.1249)


HIF-1α-IN-2 is an effective HIF-1α inhibitor with anticancer potencies (IC50s of 28 nM and 15 nM in MDA-MB-231 and MiaPaCa-2 cells, respectively). HIF-1α-IN-2?suppresses HIF-1α expression by blocking transcription and?protein translation[1].

   

(2s)-5-carbamimidamido-2-[2-(6-hydroxy-1h-indol-3-yl)-2-oxoacetamido]pentanoic acid

(2s)-5-carbamimidamido-2-[2-(6-hydroxy-1h-indol-3-yl)-2-oxoacetamido]pentanoic acid

C16H19N5O5 (361.1386)


   

(2r,3r,4s,5s,6r)-2-({6-[(z)-(hydroxyimino)methyl]-[2,2'-bipyridin]-4-yl}oxy)-6-methyloxane-3,4,5-triol

(2r,3r,4s,5s,6r)-2-({6-[(z)-(hydroxyimino)methyl]-[2,2'-bipyridin]-4-yl}oxy)-6-methyloxane-3,4,5-triol

C17H19N3O6 (361.1274)


   

7,9,9-trimethoxy-13-methyl-10-azapentacyclo[9.7.1.0²,¹⁰.0³,⁸.0¹⁵,¹⁹]nonadeca-1,3(8),4,6,11,13,15(19),16-octaen-18-one

7,9,9-trimethoxy-13-methyl-10-azapentacyclo[9.7.1.0²,¹⁰.0³,⁸.0¹⁵,¹⁹]nonadeca-1,3(8),4,6,11,13,15(19),16-octaen-18-one

C22H19NO4 (361.1314)


   

2-[(1z,2s,3s,4s,6r)-2,4-dihydroxy-3-methoxy-6-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}cyclohexylidene]acetonitrile

2-[(1z,2s,3s,4s,6r)-2,4-dihydroxy-3-methoxy-6-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}cyclohexylidene]acetonitrile

C15H23NO9 (361.1373)


   

5-carbamimidamido-2-[2-(6-hydroxy-1h-indol-3-yl)-2-oxoacetamido]pentanoic acid

5-carbamimidamido-2-[2-(6-hydroxy-1h-indol-3-yl)-2-oxoacetamido]pentanoic acid

C16H19N5O5 (361.1386)


   

(2r)-5-carbamimidamido-2-[2-(6-hydroxy-1h-indol-3-yl)-2-oxoacetamido]pentanoic acid

(2r)-5-carbamimidamido-2-[2-(6-hydroxy-1h-indol-3-yl)-2-oxoacetamido]pentanoic acid

C16H19N5O5 (361.1386)


   

2-[(1e,2s,3r,4s,6r)-2,3-dihydroxy-4-methoxy-6-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}cyclohexylidene]acetonitrile

2-[(1e,2s,3r,4s,6r)-2,3-dihydroxy-4-methoxy-6-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}cyclohexylidene]acetonitrile

C15H23NO9 (361.1373)


   

4-[(2,2-dimethylchromen-6-yl)methyl]-5-hydroxy-3-(4-hydroxyphenyl)pyrrol-2-one

4-[(2,2-dimethylchromen-6-yl)methyl]-5-hydroxy-3-(4-hydroxyphenyl)pyrrol-2-one

C22H19NO4 (361.1314)


   

2-({6-[(hydroxyimino)methyl]-[2,2'-bipyridin]-4-yl}oxy)-6-methyloxane-3,4,5-triol

2-({6-[(hydroxyimino)methyl]-[2,2'-bipyridin]-4-yl}oxy)-6-methyloxane-3,4,5-triol

C17H19N3O6 (361.1274)